Acadia Pharmaceuticals (ACAD) insider trading in the last 6 months

3 insiders sold $616K. No buys.

Quality Score4Below Average

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

See all 4 tradesSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Form 4 filings, newest first

SellMark C. Schneyer$69KEVP, Chief Financial Officerat $20.88 on Oct 30, filed Oct 30

SellMark C. SchneyerEVP, Chief Financial Officer$69Kat $20.88 on Oct 30, filed Oct 30

SellElizabeth H.z. Thompson$431KEVP, Head of Research & Devat $26.13 on Jul 30, filed Jul 31

SellElizabeth H.z. ThompsonEVP, Head of Research & Dev$431Kat $26.13 on Jul 30, filed Jul 31

SellElizabeth H.z. Thompson$1KEVP, Head of Research & Devat $26.17 on Jul 30, filed Jul 31

SellElizabeth H.z. ThompsonEVP, Head of Research & Dev$1Kat $26.17 on Jul 30, filed Jul 31

From SEC Form 4s, the newest filed Oct 30, 2026 · Insiders have 2 business days to file a trade

Pro members see every filing on ACAD with what each insider bought or sold and at what price, and can turn on an optional alert when an insider buys.

Who files at Acadia Pharmaceuticals

Insider trades by person

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Questions about ACAD's insider trades

As of Nov 10, 2026: Acadia Pharmaceuticals (ACAD) has 4 insider filings on record in the last 6 months, the newest filed Oct 30, 2026. Its Quality Score is 4 (Below Average). Scores as of 11:35 PM ET, 15 minutes behind.

Are ACAD insiders buying or selling?

3 insiders sold $616K across 4 filings in the last 6 months. No open-⁠market buys on record. The newest filing: Mark C. Schneyer, EVP, Chief Financial Officer, sold $69K on Oct 30, 2026.

Who are ACAD's biggest insider sellers?

By the dollars of their sales in the last 6 months: Elizabeth H.z. Thompson (EVP, Head of Research & Dev), 2 sales; James Kihara (Principal Accounting Officer), 1 sale; Mark C. Schneyer (EVP, Chief Financial Officer), 1 sale.

When did an ACAD insider last buy?

No ACAD insider bought shares on the open market in the last 6 months, as filed on Form 4. The newest filing is a sale by Mark C. Schneyer on Oct 30, 2026.

Acadia Pharmaceuticals's page has its Quality Score, its chart, and its earnings. More in Healthcare and Biotech.

Acadia Pharmaceuticals (ACAD) insider trading in the last 6 months

Form 4 filings, newest first

Who files at Acadia Pharmaceuticals

Questions about ACAD's insider trades

Every insider trade, with its stock's score.